CLINICAL FEATURES AND PROGNOSES OF PRIMARY GASTRIC DIFFUSE LARGE B CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS OF 139 CHINESE CASES WITH IMMUNOPHENOTYPING FROM CLAP
Y. Song,X. Cen,M. Wu,Y. Shen,X. Leng,L. Ping,Y. Xie,J. Zhu
DOI: https://doi.org/10.1002/hon.2439_138
IF: 4.85
2017-01-01
Hematological Oncology
Abstract:Introduction: Diffuse large B cell lymphoma (DLBCL) can be classified into germinal center B-cell-like (GCB) and non-GCB subtypes with immunophenotyping. Non-GCB subtype showed poorer survival than GCB subtype in most studies. Primary gastric DLBCL (PGDLBCL) is relative common in China with good outcome. We carried out a retrospective analysis of 139 cases to characterize the clinical features and prognostic factors of PGDLBCL with different immunophenotypes. Methods: From two centers of the China Lymphoma Patient Registry (CLAP), 139 PGDLBCL cases (from January 1994 to December 2015) were retrospectively analyzed. They were categorized into GCB (51 cases) and non-GCB (88 cases) subtypes according to the expression of CD10, Bcl6 and MUM1. Results: Pathological specimens were acquired by gastroscopy biopsy (114 cases) and surgery (25 cases). The following properties were similar in GCB and non-GCB PGDLBCL (p > 0.05): Lugano stage, B symptom, ECOG, International Prognosis Index, lesion location, and gastrointestinal bleeding before treatment. The 3-year progression-free survival (PFS) and 3-year overall survival (OS) of the entire cohort were 78.1% and 81.6% (the median follow-up time was 38.5 months). Patients with GCB did not show any statistically significant difference in survival from those with non-GCB (PFS: 80.5% vs. 76.8%, p = 0.161; OS: 80.5% vs. 82.5%, p = 0.901). Positive expression of Bcl6 (75.1% vs. 93.5%, p = 0.004) and Bcl2 (69.7% vs. 87.7%, p = 0.039) both correlated with poor OS, compared to specimens lacking these two biomarkers. Most patients (94.2%) received chemotherapy ± surgery as initial treatment, while others only received surgery or watch and wait. In the chemotherapy-treated cohort, patients received rituximab-combined chemotherapy appeared to have better outcome, but without statistically significance (PFS: 80.7% vs. 68.0%, p = 0.457; OS: 86.2% vs. 67.8%, p = 0.124). Rituximab did not show clinical benefit in either GCB or non-GCB subtype(p > 0.05). Treatment-related complications included gastrointestinal bleeding (8 cases), perforation (3 cases), and obstruction (2 cases), which showed no correlation with immunophenotypes. Conclusions: This retrospective study revealed that PGDLBCL with different immunophenotypes had similar clinical features, treatment-related complications, and outcome. The positive expression of Bcl2 or Bcl6 predicts poor OS in PGDLBCL. Keywords: extranodal lymphomas; germinal center B cell-like (GCB).